OCHNCNP-1 is under clinical development by EA Pharma and currently in Phase II for Relapsing Remitting Multiple Sclerosis (RRMS). According to GlobalData, Phase II drugs for Relapsing Remitting Multiple Sclerosis (RRMS) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OCHNCNP-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OCHNCNP-1 overview

Small molecule is under investigation for the treatment of Crohn’s disease, relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS). It is administered through oral route. The drug candidate is an analogue of glycolipid α – galactosylceramide (α- GalCer).

EA Pharma overview

EA Pharma, formerly Ajinomoto Pharmaceuticals, a subsidiary of Eisai Co Ltd, is a clinical research organization that develops, manufactures and sells pharmaceutical products. The organization develops pharmaceutical products based on amino acid-related technologies for the treatment of gastrointestinal and metabolic diseases. Its pipeline products are used for ulcerative colitis, osteoporosis and chronic constipation diseases. EA Pharma provides drug discovery, production and logistics, sales and marketing, and research and development services. The organization serves various sectors such as medicine and healthcare. It markets its products through its network of distributors. EA Pharma is headquartered in Tokyo, Japan.

For a complete picture of OCHNCNP-1’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.